Effects of MK-801 treatment across several pre-clinical analyses including a novel assessment of brain metabolic function utilizing PET and CT fused imaging in live rats

Neuropharmacology

Volumn 77, Issue , 2014, Pages 325-333

  Daya, R P ^a   Bhandari, J K ^a   Hui, P A ^a   Tian, Y ^a   Farncombe, T ^a   Mishra, R K ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Animal model; MK 801; PET and CT fused imaging; Schizophrenia

Indexed keywords

DIZOCILPINE; FLUORODEOXYGLUCOSE F 18; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN METABOLISM; BRAIN REGION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; FRONTAL LOBE; HYPERFRONTALITY; IMAGE RECONSTRUCTION; LOCOMOTION; MALE; MEMORY; NONHUMAN; PET SCANNER; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SENSORIMOTOR FUNCTION; SOCIAL INTERACTION; TASK PERFORMANCE; VALIDITY;

ANIMAL MODEL; MK-801; PET AND CT FUSED IMAGING; SCHIZOPHRENIA;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; EXCITATORY AMINO ACID ANTAGONISTS; MALE; MAZE LEARNING; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SENSORY GATING;

EID: 84887265311     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2013.10.001     Document Type: Article

References (58)

1. A. Abbott Schizophrenia: the drug deadlock Nature 468 2010 158 159
2. M.E. Bardgett, M. Points, C. Ramsey-Faulkner, J. Topmiller, J. Roflow, T. McDaniel, T. Lamontagne, and M.S. Griffith The effects of clonidine on discrete-trial delayed spatial alternation in two rat models of memory loss Neuropsychopharmacology 33 2008 1980 1991 (Pubitemid 351832596)
3. S. Basu, T.C. Kwee, S. Surti, E.A. Akin, D. Yoo, and A. Alavi Fundamentals of PET and PET/CT imaging Ann. N. Y. Acad. Sci. 1228 2011 1 18
4. T.M. Blodgett, C.C. Meltzer, and D.W. Townsend PET/CT: form and function Radiology 242 2007 360 385 (Pubitemid 46150968)
5. N.G. Bowery, E.H. Wong, and A.L. Hudson Quantitative autoradiography of [3H]-MK-801 binding sites in mammalian brain Br. J. Pharmacol. 93 1988 944 954 (Pubitemid 18093405)
6. M.S. Buchsbaum, K.H. Nuechterlein, R.J. Haier, J. Wu, N. Sicotte, E. Hazlett, R. Asarnow, S. Potkin, and S. Guich Glucose metabolic rate in normals and schizophrenics during the Continuous Performance Test assessed by positron emission tomography Br. J. Psychiatry 156 1990 216 227 (Pubitemid 20071995)
7. E. Bullmore, M. Brammer, S.C. Williams, V. Curtis, P. McGuire, R. Morris, R. Murray, and T. Sharma Functional MR imaging of confounded hypofrontality Hum. Brain Mapp. 8 1999 86 91 (Pubitemid 29480293)
8. S.M. Cochran, M. Kennedy, C.E. McKerchar, L.J. Steward, J.A. Pratt, and B.J. Morris Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: differential modulation by antipsychotic drugs Neuropsychopharmacology 28 2003 265 275
9. J.T. Coyle Glutamate and schizophrenia: beyond the dopamine hypothesis Cell Mol. Neurobiol. 26 2006 365 384
10. J.T. Coyle NMDA receptor and schizophrenia: a brief history Schizophr. Bull. 38 2012 920 926
11. L.L. Davidson, and R.W. Heinrichs Quantification of frontal and temporal lobe brain-imaging findings in schizophrenia: a meta-analysis Psychiatry Res. 122 2003 69 87 (Pubitemid 36506475)
12. P.L. Davis-Macnevin, J. Dekraker, L. Ladouceur, and M.R. Holahan Comparison of the MK-801-induced increase in non-rewarded appetitive responding with dopamine agonists and locomotor activity in rats J. Psychopharmacol. 27 9 2013 854 864
13. G.E. Duncan, J.N. Leipzig, R.B. Mailman, and J.A. Lieberman Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation Brain Res. 812 1998 65 75 (Pubitemid 29005332)
14. G.E. Duncan, S. Miyamoto, J.N. Leipzig, and J.A. Lieberman Comparison of brain metabolic activity patterns induced by ketamine, MK-801 and amphetamine in rats: support for NMDA receptor involvement in responses to subanesthetic dose of ketamine Brain Res. 843 1999 171 183 (Pubitemid 29488707)
15. B.A. Dyck, M.G. Beyaert, M.A. Ferro, and R.K. Mishra Medial prefrontal cortical synapsin II knock-down induces behavioral abnormalities in the rat: examining synapsin II in the pathophysiology of schizophrenia Schizophr. Res. 130 2011 250 259
16. A. Egerton, L. Reid, S. McGregor, S.M. Cochran, B.J. Morris, and J.A. Pratt Subchronic and chronic PCP treatment produces temporally distinct deficits in attentional set shifting and prepulse inhibition in rats Psychopharmacology (Berl) 198 2008 37 49
17. S.E. File The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs J. Neurosci. Methods 2 1980 219 238 (Pubitemid 10050361)
18. A.C. Foster, R. Gill, J.A. Kemp, and G.N. Woodruff Systemic administration of MK-801 prevents N-methyl-d-aspartate-induced neuronal degeneration in rat brain Neurosci. Lett. 76 1987 307 311 (Pubitemid 17070557)
19. A.C. Foster, and E.H. Wong The novel anticonvulsant MK-801 binds to the activated state of the N-methyl-d-aspartate receptor in rat brain Br. J. Pharmacol. 91 1987 403 409 (Pubitemid 17083987)
20. X.M. Gao, K. Sakai, R.C. Roberts, R.R. Conley, B. Dean, and C.A. Tamminga Ionotropic glutamate receptors and expression of N-methyl-d-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia Am. J. Psychiatry 157 2000 1141 1149 (Pubitemid 30432497)
21. X.M. Gao, O. Shirakawa, F. Du, and C.A. Tamminga Delayed regional metabolic actions of phencyclidine Eur. J. Pharmacol. 241 1993 7 15 (Pubitemid 23268330)
22. M.A. Geyer, K. Krebs-Thomson, D.L. Braff, and N.R. Swerdlow Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review Psychopharmacology (Berl) 156 2001 117 154 (Pubitemid 32702206)
23. G. Gilmour, E.Y. Pioli, S.L. Dix, J.W. Smith, M.W. Conway, W.T. Jones, S. Loomis, R. Mason, S. Shahabi, and M.D. Tricklebank Diverse and often opposite behavioural effects of NMDA receptor antagonists in rats: implications for "NMDA antagonist modelling" of schizophrenia Psychopharmacology (Berl) 205 2009 203 216
24. D.C. Glahn, J.D. Ragland, A. Abramoff, J. Barrett, A.R. Laird, C.E. Bearden, and D.I. Velligan Beyond hypofrontality: a quantitative meta-analysis of functional neuroimaging studies of working memory in schizophrenia Hum. Brain Mapp. 25 2005 60 69 (Pubitemid 40656193)
25. C. Grillon, R. Ameli, D.S. Charney, J. Krystal, and D. Braff Startle gating deficits occur across prepulse intensities in schizophrenic patients Biol. Psychiatry 32 1992 939 943 (Pubitemid 23024906)
26. R.F. Halliwell, J.A. Peters, and J.J. Lambert The mechanism of action and pharmacological specificity of the anticonvulsant NMDA antagonist MK-801: a voltage clamp study on neuronal cells in culture Br. J. Pharmacol. 96 1989 480 494 (Pubitemid 19045126)
27. K. Hill, L. Mann, K.R. Laws, C.M. Stephenson, I. Nimmo-Smith, and P.J. McKenna Hypofrontality in schizophrenia: a meta-analysis of functional imaging studies Acta Psychiatr. Scand. 110 2004 243 256 (Pubitemid 39278982)
28. H.H. Holcomb, A.C. Lahti, D.R. Medoff, T. Cullen, and C.A. Tamminga Effects of noncompetitive NMDA receptor blockade on anterior cingulate cerebral blood flow in volunteers with schizophrenia Neuropsychopharmacology 30 2005 2275 2282 (Pubitemid 41643980)
29. C.A. Jones, D.J. Watson, and K.C. Fone Animal models of schizophrenia Br. J. Pharmacol. 164 2011 1162 1194
30. V. Labrie, and J.C. Roder The involvement of the NMDA receptor D-serine/glycine site in the pathophysiology and treatment of schizophrenia Neurosci. Biobehav. Rev. 34 2010 351 372
31. A.C. Lahti, B. Koffel, D. LaPorte, and C.A. Tamminga Subanesthetic doses of ketamine stimulate psychosis in schizophrenia Neuropsychopharmacology 13 1995 9 19
32. Z. Li, C.H. Kim, J. Ichikawa, and H.Y. Meltzer Effect of repeated administration of phencyclidine on spatial performance in an eight-arm radial maze with delay in rats and mice Pharmacol. Biochem. Behav. 75 2003 335 340 (Pubitemid 36859819)
33. A.L. Lim, D.A. Taylor, and D.T. Malone Consequences of early life MK-801 administration: long-term behavioural effects and relevance to schizophrenia research Behav. Brain Res. 227 2012 276 286
34. J. McGrath, S. Saha, D. Chant, and J. Welham Schizophrenia: a concise overview of incidence, prevalence, and mortality Epidemiol. Rev. 30 2008 67 76
35. S. Miyamoto, J.N. Leipzig, J.A. Lieberman, and G.E. Duncan Effects of ketamine, MK-801, and amphetamine on regional brain 2-deoxyglucose uptake in freely moving mice Neuropsychopharmacology 22 2000 400 412 (Pubitemid 30105768)
36. V. Molina, S. Solera, J. Sanz, F. Sarramea, R. Luque, R. Rodriguez, M.A. Jimenez-Arriero, and T. Palomo Association between cerebral metabolic and structural abnormalities and cognitive performance in schizophrenia Psychiatry Res. 173 2009 88 93
37. J.C. Neill, S. Barnes, S. Cook, B. Grayson, N.F. Idris, S.L. Mclean, S. Snigdha, L. Rajagopal, and M.K. Harte Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism Pharmacol. Ther. 128 2010 419 432
38. D.S. Olton The radial arm maze as a tool in behavioral pharmacology Physiol. Behav. 40 1987 793 797 (Pubitemid 17157679)
39. T.A. Paine, and W.A. Carlezon Effects of antipsychotic drugs on MK-801-induced attentional and motivational deficits in rats Neuropharmacology 56 2009 788 797
40. E. Parellada, A.M. Catafau, M. Bernardo, F. Lomena, E. Gonzalez-Monclus, and J. Setoain Prefrontal dysfunction in young acute neuroleptic-naive schizophrenic patients: a resting and activation SPECT study Psychiatry Res. 55 1994 131 139 (Pubitemid 24301594)
41. R.G. Paulman, M.D. Devous Sr., R.R. Gregory, J.H. Herman, L. Jennings, F.J. Bonte, H.A. Nasrallah, and J.D. Raese Hypofrontality and cognitive impairment in schizophrenia: dynamic single-photon tomography and neuropsychological assessment of schizophrenic brain function Biol. Psychiatry 27 1990 377 399 (Pubitemid 20083767)
42. L.S. Pilowsky, R.A. Bressan, J.M. Stone, K. Erlandsson, R.S. Mulligan, J.H. Krystal, and P.J. Ell First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients Mol. Psychiatry 11 2006 118 119 (Pubitemid 43164609)
43. J. Pratt, C. Winchester, N. Dawson, and B. Morris Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap Nat. Rev. Drug Discov. 11 2012 560 579
44. I.J. Reynolds, S.N. Murphy, and R.J. Miller 3H-labeled MK-801 binding to the excitatory amino acid receptor complex from rat brain is enhanced by glycine Proc. Natl. Acad. Sci. U. S. A 84 1987 7744 7748 (Pubitemid 18035730)
45. I.J. Reynolds, and A.M. Palmer Regional variations in [3H]MK801 binding to rat brain N-methyl-d-aspartate receptors J. Neurochem. 56 1991 1731 1740
46. F. Sams-Dodd Effects of continuous D-amphetamine and phencyclidine administration on social behaviour, stereotyped behaviour, and locomotor activity in rats Neuropsychopharmacology 19 1998 18 25 (Pubitemid 28255210)
47. F. Sams-Dodd Phencyclidine in the social interaction test: an animal model of schizophrenia with face and predictive validity Rev. Neurosci. 10 1999 59 90 (Pubitemid 29396547)
48. P. Seeman, H.C. Guan, and H. Hirbec Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil Synapse 63 2009 698 704
49. P. Seeman, and M. Lasaga Dopamine agonist action of phencyclidine Synapse 58 2005 275 277 (Pubitemid 41690812)
50. A. Seillier, and A. Giuffrida Evaluation of NMDA receptor models of schizophrenia: divergences in the behavioral effects of sub-chronic PCP and MK-801 Behav. Brain Res. 204 2009 410 415
51. E.H. Simpson, C. Kellendonk, and E. Kandel A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia Neuron 65 2010 585 596
52. R. Sircar, M. Rappaport, R. Nichtenhauser, and S.R. Zukin The novel anticonvulsant MK-801: a potent and specific ligand of the brain phencyclidine/sigma-receptor Brain Res. 435 1987 235 240 (Pubitemid 18009792)
53. M. Soyka, W. Koch, H.J. Moller, T. Ruther, and K. Tatsch Hypermetabolic pattern in frontal cortex and other brain regions in unmedicated schizophrenia patients. Results from a FDG-PET study Eur. Arch. Psychiatry Clin. Neurosci. 255 2005 308 312 (Pubitemid 41618802)
54. E.A. Spieker, R.S. Astur, J.T. West, J.A. Griego, and L.M. Rowland Spatial memory deficits in a virtual reality eight-arm radial maze in schizophrenia Schizophr. Res. 135 2012 84 89
55. T. Uehara, T. Sumiyoshi, T. Seo, H. Itoh, T. Matsuoka, M. Suzuki, and M. Kurachi Long-term effects of neonatal MK-801 treatment on prepulse inhibition in young adult rats Psychopharmacology (Berl) 206 2009 623 630
56. 18F]fluorodeoxyglucose (FDG) Eur. Neuropsychopharmacol. 7 1997 9 24 (Pubitemid 27139716)
57. E.H. Wong, J.A. Kemp, T. Priestley, A.R. Knight, G.N. Woodruff, and L.L. Iversen The anticonvulsant MK-801 is a potent N-methyl-d-aspartate antagonist Proc. Natl. Acad. Sci. U. S. A 83 1986 7104 7108 (Pubitemid 16002378)
58. E.H. Wong, A.R. Knight, and G.N. Woodruff [3H]MK-801 labels a site on the N-methyl-d-aspartate receptor channel complex in rat brain membranes J. Neurochem. 50 1988 274 281 (Pubitemid 18023510)